Natural Cure

Baxter says trial on new flu shot promising

Baxter International Inc., working to modernize the production of influenza vaccines, this morning said its seasonal flu product is showing "strong antibody responses and good tolerability" in an early stage clinical trial in humans.

Although Baxter is still several years from winning approval of the product, the study shows Baxter's reformulated seasonal flu vaccine is tolerable. In late 2004, Baxter had to suspend final-stage human sudy of its seasonal flu vaccine because it was causing fevers in some patients.

The Deerfield-based medical product giant is trying to develop a flu vaccine produced with cell tissues, which is a method that would allow manufacturers to quickly brew vaccine by the vat and likely eliminate shortages like the one that rattle U.S. consumers and health-care providers from time to time.
The cell-based approach is a sharp contrast to the tedious, 1940s method still used today that involves hand-processing millions of chicken eggs in labs. For each dosers shine a light through the shell of an egg to find the fluid surrounding an embryo, inject a strain of the flu virus and let it incubate for several months.

The current method is a long months-long process fraught with risk, while cell-based vaccines are more consistent and could be produced in as little as nine to 12 weeks.

In the latest clinical trial, Baxter said more than 900 patients were studied. Baxter said the preliminary data show its cell-based seasonal influenza vaccine's "tolerability profile" to be similar to egg-based seasonal flu vaccines on the market. There were, however, some side effects that included headaches and some injection site reactions, Baxter said.

Baxter is building momentum for its vaccines business. The company is also in the final stages of testing for a vaccine against strains of the Avian influenza, also known as the bird flu and is working with governments around the world interested in stockpiling the product in the event of a pandemic outbreak. Chicago Tribune

New research into urologic conditions - such as erectile dysfunction - indicate that these disorders could be associated with or precursors to more serious conditions, and suggest a need for practitioners to view these diseases in the greater context of total health as opposed to isolated disorders. A special session highlighting the association on urologic diseases with non-urologic conditions such as heart disease and metabolic syndrome was presented during the 102nd Annual Scientific Meeting of the American Urological Association. A special session for the media was moderated by Marshall L. Stoller, M.D.

ENDOTHELIAL DYSFUNCTION AND OXIDATIVE STRESS ASSOCIATED WITH THE METABOLIC SYNDROME CAN BE REVERSED BY A CHRONIC TREATMENT WITH SILDENAFIL (Abstract 686)

Metabolic syndrome is characterized by a number of conditions, including elevated blood pressure, excess body fat around the waist and insulin resistance. Many patients with these conditions also exhibit endothelial dysfunction with increases in oxidative stress and decreases in nitric oxide production - which has been related to erectile dysfunction (ED). Researchers from France explored whether treatment with sildenafil citrate - a common pharmacologic treatment for Erectile Dysfunction - could improve endothelial dysfunction in a rat model.

Researchers administered sildenafil to fructose-fed rats to achieve plasma concentrations known to give efficacy in men and observed endothelial function and oxidative stress in the animals during treatment and one-week after treatment had been stopped. It was observed that chronic sildenafil treatment improved endothelial function and oxidative stress, suggesting that this treatment could be a benefit for cardiovascular indications as well as erectile dysfunction.

ERECTILE DYSFUNCTION AND CORONARY HEART DISEASE (Abstract 864)

Research has shown a connection between erectile dysfunction (ED) and cardiovascular disease (CVD) in men, and has established a need to consider one a precursor to the other. Researchers further evaluated the association of these two conditions and whether the association could be age-related.

A random sample of men from the Olmsted County population was evaluated by questionnaire, and community medical records of the subjects were examined. Logistical regression models examined the associations between ED and CVD. Men with CVD were 4.2 times more likely to have ED than men without heart disease. The results underscore a need to consider sexual function in men with heart disease and CVD in men with ED.

Source: Medicalnewstoday

In a new study that will be published in the July 17th issue of the journal Circulation, Canadian researchers reveal that the erectile dysfunction drug Viagra (Sildenafil), may likely be effective in the treatment of patients with right-sided heart failure, principally because their study shows that only the hearts of these patients exhibit the target molecules that can be blocked by these types of drugs.

The study was led by Drs. Jayan Nagendran, a cardiac surgery resident and Evangelos Michelakis, professor in the Department of Surgery and the Department of Pharmacology at the University of Alberta in Canada.

The researchers wanted to gain insight into the mechanism of how Viagra may benefit patients with pulmonary hypertension (high blood pressure in the lung vessels). This devastating condition usually leads to right-sided (right ventricle) heart failure.

In their study, the researchers evaluated heart specimens from 9 patients to assess their phosphodiesterase type-5 (PDE-5) activity and their response to specific type-5 PDE inhibitors such as Viagra.

PDE-5 is an enzyme that degrades the activity of cGMP, a chemical that relaxes smooth muscle cells. In the vasculature, relaxation of smooth muscle cells causes vessels to dilate thereby increasing blood flow.

PDE-5 is preponderant in the corpus cavernosum of the penis. When it's inhibited, it leads to higher cGMP levels and less dilation (more constriction) of the blood vessels that let blood escape from the corpus cavernosum and thereby leading to a sustained erection.

The researchers essentially found that PDE-5 was not expressed in heart samples from patients that were healthy. Conversely, they did discover that patients with enlarged right heart ventricles had marked increased PDE-5 activity.

When the research team used Viagra (the PDE-5 inhibitor) in their experiments, they found that it increased the activity of isolated cardiac cells and the strength of heart contractions only in unhealthy samples and patients and not in any of the healthy controls.

In the press release from the University of Alberta, Dr. Nagendran stated that "there are a number of medical conditions in both children and adults for which there is a need to boost the performance of the right ventricle, and this drug can be clinically and immediately relevant to help these patients"

Dr. Michelakis also added that "We have a number of drugs and therapies available to treat the left ventricle of the heart to prevent it from failing or to treat it after it has failed, bet we don't have anything for the right ventricle. The phosphodiesterase type-5 inhibtors, which include Viagra and similar other drugs may offer some important benefits in this case."

Viagra (Sildenafil) has been recently approved in the treatment of pulmonary hypertension.

Source: Associatedcontent

ED affects up to 50 per cent of men at some point in their lives and is generally treated with the use of oral medications like Cialis, Viagra and Levitra. A study by a psychologist finds oral drugs like Viagra improve sexual performance but not a man’s ‘sexual health’. Not to worry, another new study finds Viagra can improve heart function and potentially save the lives of people with specific heart problems. The net results imply a longer life with poor sexual health but good ‘sexual function’.

Viagra is a magic blue pill used to treat erectile dysfunction among men and can be obtained on prescription from anywhere. A new study finds Viagra can improve heart function and potentially save the lives of people with specific heart problems.

Erectile dysfunction (ED) or impotence as it is often called, affects men of all ages. There was a time when treatments were few and success of treatment was rare. That was before the ED drug everyone has heard of. That was before "the little blue pill." That was before Viagra.

Viagra (sildenafil) belongs to a group of medicines that delay the enzymes called phosphodiesterase from working too quickly. By controlling phosphodiesterase, sildenafil helps to maintain an erection that is produced when the penis is physically stimulated. We have all heard of the popularity of Viagra. In fact, men of all ages are finding a new found sexual youth because of the little blue pill. But like any prescription medication, Viagra is not without its pitfalls and problems however.

Source: About